A Novel Polymersome Nanocarrier Promotes Anti‐Tumour Immunity by Improved Priming of CD8 + T Cells
Immunology · 2025
DOI: 10.1111/imm.13903 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, 2025. Verfasst von Regine J Dress und 13 weiteren Autor:innen. Beteiligte Einrichtung: Singapore Immunology Network (SIgN), A*STAR, Singapore, Singapore. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Cancer Vaccines, Nanoparticles, Polymers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: A*STAR UIBR award, BMRC transition funds, BMRC.
Abstract (Originalsprache)
Cancer is one of the leading causes of death worldwide. In recent years, immune checkpoint inhibitor therapies, in addition to standard immuno‐ or chemotherapy and surgical approaches, have massively improved the outcome for cancer patients. However, these therapies have their limitations and improved strategies, including access to reliable cancer vaccines, are needed. Here, we describe the use of self‐assembling artificial cell membrane (ACM) polymersomes to deliver tumour‐specific peptides to trigger sustainable and efficient anti‐tumour immune responses. We found that ACM polymersomes were highly efficient in targeting and activating mononuclear phagocytes (MNP) including dendritic cells (DC), while providing long‐term reservoirs of antigens for continued immune cell priming. Subcutaneous injection of ACM‐encapsulated tumour‐antigen‐peptides into tumour‐bearing mice resulted in improved priming of CD8 + T cells and increased generation of tumour‐antigen‐peptide specific CD8 + effector T cells. Prophylactic and therapeutic immunisation with ACM‐encapsulated peptides resulted in changes to the MNP composition in the tumour microenvironment, tumour regression and improved survival of immunised mice. Combining anti‐PD‐1 immune checkpoint inhibitor therapy with ACM polymersome peptide delivery further boosted anti‐tumour immunity. Our results show that ACM polymersome nanocarriers efficiently instruct anti‐tumour immune responses offering a promising new approach for vaccination and cancer immunotherapy. Trial Registration: NCT05385991
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Singapore Immunology Network (SIgN), A*STAR, Singapore, Singapore.
- Institute of Systems Immunology, Hamburg Center for Translational Immunology (HCTI), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- ACM Biolabs Pte Ltd, Singapore, Singapore.
- Sapreme Development B.V, Bilthoven, The Netherlands.
- Unilever Industries Private Limited, Singapore.
- Gustave Roussy Cancer Campus, Villejuif, France.
ORCID-Profile: Regine J Dress, Victor Ho, Jian Hang Lam, Gowshika Rengasamy, Florent Ginhoux
Förderung
- A*STAR UIBR award
- BMRC transition funds
- BMRC
- Singapore Immunology Network (SIgN) core funding
- Singapore Immunology Network
Zitieren
APA
Dress, R. J., Ho, W. W., Ho, V., Lam, J. H., Décaillot, F. M., Sinsinbar, G., Soo, J., Rengasamy, G., Khan, A. K., Cornell, T. A., Chia, T. W., Venkataraman, S., Nallani, M., & Ginhoux, F. (2025). A Novel Polymersome Nanocarrier Promotes Anti‐Tumour Immunity by Improved Priming of CD8 + T Cells. Immunology. https://doi.org/10.1111/imm.13903
Vancouver
Dress RJ, Ho WW, Ho V, Lam JH, Décaillot FM, Sinsinbar G, et al. A Novel Polymersome Nanocarrier Promotes Anti‐Tumour Immunity by Improved Priming of CD8 + T Cells. Immunology. 2025. doi:10.1111/imm.13903
BibTeX
@article{Dress2025,
author = {Dress, Regine J and Ho, William W and Ho, Victor and Lam, Jian Hang and Décaillot, Fabien M and Sinsinbar, Gaurav and Soo, Jenetta and Rengasamy, Gowshika and Khan, Amit Kumar and Cornell, Thomas Andrew and Chia, Teck Wan and Venkataraman, Shrinivas and Nallani, Madhavan and Ginhoux, Florent},
title = {A Novel Polymersome Nanocarrier Promotes Anti‐Tumour Immunity by Improved Priming of CD8 + T Cells},
journal = {Immunology},
year = {2025},
doi = {10.1111/imm.13903}
}
EUVIMED